NeuroPace (NASDAQ:NPCE) Posts Earnings Results, Beats Estimates By $0.07 EPS

NeuroPace (NASDAQ:NPCE) announced its earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.07, Zacks reports. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.47 million during the quarter, compared to analyst estimates of $21.14 million.

NeuroPace Stock Up 0.9 %

Shares of NPCE stock opened at $11.92 on Wednesday. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace has a one year low of $5.45 and a one year high of $15.77. The company’s fifty day moving average price is $12.71 and its 200-day moving average price is $9.75. The company has a market capitalization of $355.79 million, a price-to-earnings ratio of -11.92 and a beta of 2.05.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NPCE. JPMorgan Chase & Co. upped their price objective on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Wells Fargo & Company boosted their price target on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, January 30th. Finally, UBS Group assumed coverage on NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price target for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, NeuroPace currently has an average rating of “Moderate Buy” and a consensus target price of $14.80.

Insider Buying and Selling

In other news, insider Martha Morrell sold 78,334 shares of NeuroPace stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the sale, the insider now owns 81,993 shares in the company, valued at $1,124,943.96. This trade represents a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,352,479 shares of company stock valued at $50,670,217. Company insiders own 22.20% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.